This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany. Image courtesy: European Society of Cardiology.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , revealed findings from a company-funded study of real-world data. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.
A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrial fibrillation (AF) is still reported.1 A gradual increase in arrhythmia recurrences during 12 months after catheter ablation (CA) of atrial fibrillation (AF) is still reported.1
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. 1,ii For patients who had received ablation, median procedure and fluoroscopy times were 90.0 Food & Drug Administration ( FDA ).
Asthma is a known riskfactor for atrial fibrillation (AF), the most common sustained arrhythmia. While radiofrequency catheter ablation is effective in treating AF, the impact of asthma and its severity on ablation outcomes has not been previously explored.
Multiple riskfactors for arrhythmia recurrence after Ventricular Tachycardia (VT) ablation have been identified. However, the cumulative impact of these riskfactors has not been evaluated, making it challenging to predict these risks in patients with multiple coexisting conditions.
Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.StructureAtrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally.
We present the long-term outcome of catheter ablation (CA) and electrophysiological characteristics in HIV+ AF patients. A total of 31 HIV patients and 31 controls were generated by propensity matching, based on calculated riskfactor scores, using a logistic model. vs. 54%, p < .001], vs. 45.2%, p < .001]
Atrial fibrillation, or AFib, is the most common type of heart rhythm disorder (arrhythmia), affecting over 6 million Americans, and the number is expected to double by 2030. Catheter ablation is a minimally invasive procedure that disables portions of heart tissue that cause irregular heart rhythms. “In
Cox proportional hazard analysis showed that iCS was significantly associated with the primary outcome in the unadjusted model; however, the association disappeared after adjustment for log-transformed B-type natriuretic peptide level, LVEF, a history of ventricular tachycardia/fibrillation, and ablation for ventricular tachycardia after diagnosis.
This increases the pressure inside your ear and chest, which reduces some heart arrhythmias. Maintain a Healthy Weight – Excess weight is a major riskfactor for AFib. Stay Hydrated – Experts recommend men drink about 15.5 cups of water per day and women drink about 11.5
The patient was started on amiodarone, anticoagulation, and metoprolol, and scheduled for atrial flutter ablation. He underwent ablation in the EP Lab. Is longterm endurance-training a riskfactor for AFib and AFlutter? == Why is Today's Initial Rhythm AFlutter?
Furthermore, it includes the latest recommendations which specifically address AF and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, AF catheter or surgical ablation, and riskfactor modification and AF prevention.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Patients undergoing first-time atrial fibrillation (AF) ablation can benefit from targeting non-pulmonary vein (PV) triggers. Preprocedural identification of high-risk individuals can guide planning of ablation strategy. risk), and 14.1%
Finally, apart from all the riskfactor listed above , aging, is the biggest riskfactor (Structural and Hemodynamic wear & tear ? We don’t need to think deep, to realize, modalities which take on this arrhythmia head-on has a minuscule role at the population level.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content